Addex Announces Participation in the H.C. Wainwright 25th
Geneva, Switzerland, September 6, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Source: globenewswire.com
Page 5 - Tim Dyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Tim Dyer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Tim Dyer Today - Breaking & Trending Today
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024 -Today at 01:01 am
Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex Therapeutics , a clinical-stage pharmaceutical company...
Source: marketscreener.com
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout
Cohort 1 is completed, and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 5, 2023 - Addex...
Source: globenewswire.com
Addex's Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functionsFirst time mGlu5 linked to post-strok...
Source: businessinsider.com
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update - Addex Therapeutics (NASDAQ:ADXN)
ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim Review Committee (IRC) recommendationIndivior GABAB PAM collaboration extended to June 2024 with CHF 2.7 million of
Source: benzinga.com